Almac to Demo Joint Service Offerings
Recently, Almac has enhanced its offerings by forming an exclusive integrated trial management alliance with Exco InTouch, a firm specializing in patient recruitment, retention, compliance, and ePRO services.The joint Almac-Exco InTouch service offering aims to enhance patient retention and compliance through the use of multiple technologies, such as SMS text messages and emails. The technology reminds patients to complete key elements of their required study obligations, such as taking medication, attending appointments, fasting prior to laboratory testing, filling out diaries, and others, while also collecting reasons for non-compliance. Working with sponsors on clinical trials, Almac will develop study-specific patient retention and compliance programs that will begin immediately upon randomization into the trial and remain in effect until the trial is completed.
Almac announced that the new joint services will be demonstrated at the DIA’s 23nd Annual EuroMeeting located in Berlin, Germany, March 27-28 and at the Partnerships in Clinical Trials Conference in Phoenix, Arizona, March 30 – April 1. In addition to featuring its the new integration with Exco InTouch, Almac will be demonstrating its IXRS® (Interactive Voice and Web Response) services and Almac’s Interactive Reporting solution, two services that were launched in 2010.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
